Notice of Proposed Sale · 144
Abeona Therapeutics Inc.
ABEONASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ABEONA THERAPEUTICS INC.
- Issuer CIK
- 0000318306
- SEC file number
- 001-15771
- Phone
- 646-813-4701
- Person for whose account securities are to be sold
- Seshadri Vishwas
- Relationships to issuer
- Officer
- Street
- 6555 CARNEGIE AVE, 4TH FLOOR
- City
- CLEVELAND
- State / country code
- OH
- Postal code
- 44103
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 19,608 | 101,091.00 | 57,184,017 | 09/29/2026 | Nasdaq | Stifel Nicolaus & Company Inc |
Broker / market maker — proposed row 1, entry 1
- Name
- Stifel Nicolaus & Company Inc
- Street
- 501 N Broadway
- City
- St. Louis
- State / country code
- MO
- Postal code
- 63102
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/29/2026 | Restricted Stock Awards | Issuer | 38,800 | N | 09/29/2026 | Equity Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Vishwas Seshadri | Common Stock | 07/09/2026 | 67,971 | 473,330.00 |
Seller — prior-sale row 1, entry 1
- Name
- Vishwas Seshadri
- Street
- 6555 CARNEGIE AVE
- Street (continued)
- 4TH FLOOR
- City
- CLEVELAND
- State / country code
- OH
- Postal code
- 44103
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
These shares were sold to cover for taxes pursuant to an RSA vesting event.
Notice signature
- Notice date
- 09/29/2026
- Signed
- /s/ Azad Daswani, as a duly authorized representative of STIFEL, as attorney-in-fact for Vishwas Seshadri
Company context
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.